Transplant Genomics Appoints Brett Jensen Vice President of Sales
Company Expands Leadership Team to Prepare Commercial Launch of Blood Monitoring Test for Kidney Transplant Recipients
Brookline, MA, November 12, 2014 — Transplant Genomics Inc. (TGI) today announced the appointment of senior healthcare sales and marketing leader Brett R. Jensen to the position of Vice President, Sales. In his role, Jensen will be responsible for initiating partnerships with kidney transplant centers and overseeing the company’s sales strategy as well as leading reimbursement activities.
“We are very pleased to welcome Brett to our team. He brings a wealth of experience in sales, marketing, and reimbursement that will prove invaluable as we begin commercialization of tests for minimally invasive serial monitoring of kidney transplant recipients,” commented Stan Rose, PhD, President & CEO of Transplant Genomics.
Jensen has more than 25 years of experience in business growth, organizational leadership, and product and market development in molecular diagnostics and pharmaceuticals. Prior to joining TGI, Jensen served as Sales and Marketing Director in Myriad Genetics’ urology business unit. He played a key role in reimbursement for Myriad’s prostate cancer genomic signature by obtaining a positive Draft Local Coverage Determination by Medicare and by achieving its inclusion in the National Comprehensive Cancer Network prostate cancer guidelines. He also held numerous sales and marketing positions at GlaxoSmithKline in a wide range of disease areas.
TGI will be exhibiting (Booth #638) at the American Society of Nephrology’s Kidney Week, where it will discuss opportunities for transplant nephrologists to participate in early clinical access studies using its minimally invasive test for serial monitoring of graft status in kidney transplant recipients. The test is based on analysis of gene expression signatures in whole blood, enabling differentiation between causes of graft dysfunction, and more importantly, earlier detection and prediction of graft dysfunction. TGI is preparing for a commercial launch in 2015 and plans to process patient samples at its new CLIA service lab in Pleasanton, CA.
About Transplant Genomics Inc.
Transplant Genomics Inc. (TGI) is a molecular diagnostics company committed to improving organ transplant outcomes. Working with the transplant community, TGI will deliver vital advances in diagnosis and prediction of transplant status, supporting clinicians with clear, actionable information to optimize immunosuppression therapy, enhance patient care and improve graft survival. Tests will be made commercially available through a CLIA lab, with an initial focus on kidney transplantation. www.transplantgenomics.com